Caricamento...
Immunogenicity and safety of a proposed pegfilgrastim biosimilar MSB11455 versus the reference pegfilgrastim Neulasta(®) in healthy subjects: A randomized, double‐blind trial
MSB11455 is a proposed biosimilar to the currently licensed reference pegfilgrastim (Neulasta(®)). This study was designed primarily to compare the immunogenicity of MSB11455 and Neulasta(®). As secondary objectives, the safety and tolerability of MSB11455 and Neulasta(®) were also compared. Healthy...
Salvato in:
| Pubblicato in: | Pharmacol Res Perspect |
|---|---|
| Autori principali: | , , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
John Wiley and Sons Inc.
2020
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7183238/ https://ncbi.nlm.nih.gov/pubmed/32333641 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/prp2.578 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|